Kennedy's Rebate Scheme Is Back in Court. Good.

Ten months ago, a federal judge in Maine stopped Health and Human Services Secretary Robert F. Kennedy Jr.'s 340B rebate scheme three days before it was set to take effect. The First Circuit called the government's record "threadbare." HHS gave up and agreed to vacate the program.

One week later, HRSA started building it again. Bigger.

On October 9, the American Hospital Association, the Maine Hospital Association and four safety-net hospitals went back to federal court to stop the sequel. We applaud them. Their complaint reads like an indictment.

How much will the 340B rebate program cost hospitals?

Start with the money. HRSA says hospitals and clinics will spend $537 million a year just to hand claims data to drug companies. That is the government's own number, and it is a fraction of the real bill. HRSA left out reconciliation, start-up, vendor, training and other costs. According to the complaint, the full cost conservatively exceeds $1 billion a year for 340B hospitals alone. Hospitals are only about 18 percent of covered entities. Community health centers and clinics pay on top of that.

How did HRSA get its number so low? It assumed each facility needs five hours of pharmacist time per week. Five. Last year HRSA guessed, with no explanation, two hours a week for 10 drugs. This year it proposed 25 drugs, so it multiplied by 2.5 (the final list of drugs subject to rebates came in at 21). That is the entire methodology. Vanderbilt Health told HRSA it would need six full-time employees, "48 times greater than HRSA's estimate." A study of 24 community health centers found that reconciliation alone, which HRSA never counted, would take 13 to 38 hours a week.

Why do hospitals call 340B rebates an interest-free loan to drug companies?

Then there is the float. Under rebates, hospitals pay drug companies full price upfront and wait to get their own money back. The First Circuit described it as "an interest-free loan from the hospitals to the manufacturers." Eastern Maine Medical Center would have to advance about $14 million a year. Unity Medical Center, a 14-bed critical access hospital in North Dakota with an operating margin under 3 percent, must float about $2.5 million.

HRSA's answer? It "believes" cash flow will be fine. Is it evidence? Two studies funded by the drug industry, one of which its own authors revised after discovering factual errors.

Does the 340B rebate pilot actually stop duplicate discounts?

Worse, HRSA cannot say what this scheme actually accomplishes. It conceded there is "no federal estimate" of duplicate discounts, then parroted Big Pharma's claim of up to $1.5 billion across the entire program. The pilot covers less than 5.5 percent of 340B sales. The complaint's napkin math: about $82.5 million in theoretical benefit, set against more than a billion dollars in costs.

That is not policy. That is a wealth transfer from America's safety-net hospitals to the richest industry in America.

HRSA even had a better option. The government told two federal appeals courts that manufacturers "have alternate means to deduplicate discounts." CMS opened a similar clearinghouse on October 1, the same day HRSA approved ten drug companies' rebate plans.

Who gets hurt if the 340B rebate program takes effect?

Do not call this a pilot. It applies to all of the more than 15,000 covered entities in America, from big-city teaching hospitals to small-town clinics. Participation is mandatory for hospitals and voluntary for drug companies. It is Secretary Kennedy's department, and his name is first on the defendants' list. He owns it.

The harm is not abstract. Dallas County Medical Center in Arkansas runs a cancer telehealth clinic that spares patients a two-hour round trip drive, plus a senior psychiatric program that is the only mental health counseling in the county. The complaint says the rebate scheme puts both at risk.

The case is before Chief Judge Lance Walker, the same judge who saw through the first scheme. PhRMA and three drug companies have now pushed their way into the case to defend HRSA. Let them. The facts have not changed, and neither has the law.

Big Pharma wants to be paid upfront. America's patients cannot afford the bill. Judge Walker stood up for them once. He has every reason to do it again.

How we got these numbers. Every figure in this post comes from the hospitals' complaint in American Hospital Association v. Kennedy, No. 1:26-cv-00515-LEW (D. Me., filed Oct. 9, 2026). HRSA's $537,222,270 cost estimate and its five-hours-per-week assumption are the agency's own figures, as cited in the complaint (paragraphs 13 and 14). The complaint traces the five hours to HRSA's unexplained 2025 estimate of two hours, multiplied by 2.5 when the proposed drug list grew from 10 to 25 (paragraph 68). The $1 billion-plus hospital cost estimate, the float amounts, the Vanderbilt staffing figure and the National Association of Community Health Centers time study come from the administrative record and plaintiff declarations described in the complaint (paragraphs 13, 77, 133 and 206). The $82.5 million benefit ceiling is the complaint's own calculation: 5.5 percent, HRSA's stated share of 340B sales covered by the pilot, applied to the $1.5 billion duplicate-discount figure HRSA cited from drug manufacturers (paragraph 19).